Imexpharm Corp

Imexpharm Corp maintains a conservative capital structure with a debt-to-equity ratio of 0.09 and a current ratio of 4.05, indicating strong short-term liquidity coverage. The balance sheet shows total equity of 2,306,522,178,890 VND against total liabilities of 476,112,306,330 VND, with long-term debt standing at 212,779,232,150 VND. Cash and equivalents are reported at 130,000,000,000 VND. Despite the strong current ratio, the risk assessment flags medium liquidity risk and notes that net cash is negative after subtracting total debt, suggesting potential off-balance-sheet obligations or classification nuances in the debt figures.

Profitability metrics appear exceptionally high relative to market valuation, with a return on equity of 15.89% and return on assets of 13.17%. The company generated net income of 349,138,023,400 VND on revenue of 2,441,085,482,090 VND, resulting in a net margin of approximately 14.3%. Operating income was 445,002,831,190 VND, yielding an operating margin of roughly 18.2%. These returns are significantly elevated compared to typical industry medians for integrated oil and gas or pharmaceuticals, suggesting either a niche market position, low capital intensity, or potential accounting anomalies given the extreme valuation multiples.

Imexpharm Corp (IMP.HM) has experienced significant volatility in its shareholder registry, marked by major severity holder changes detected between July 4 and July 12, 2026. These signals indicate substantial modifications in shareholdings for specific investors, including investor ID 931 and investor ID 587, with share counts fluctuating dramatically within the same reporting period. For instance, investor ID 931’s holdings were recorded shifting between 18 and 1,290 shares, while investor ID 587 saw a reported adjustment from 134,118 shares down to 498 shares as of March 31, 2026. Despite these active movements in the ownership structure, the company’s fundamental profile remains stable with no material changes reported against prior analysis. The COMPANY_360 data confirms that Imexpharm Corp, also known as Imperial Oil Ltd, maintains a consistent operational footprint with zero officers listed and no index memberships. This stability in core corporate metrics contrasts with the dynamic nature of the recent holder adjustments, suggesting that the changes are isolated to specific investment positions rather than broader corporate restructuring. The significance of these holder changes lies in the concentration of ownership activity among a limited number of top holders. With 31 top holders identified and only three analysts covering the stock, the market’s attention is likely focused on these specific institutional or major shareholder movements. The repeated detection of major severity changes for the same investor IDs within a short timeframe highlights a period of active portfolio rebalancing or data correction for these key stakeholders. Ultimately, while the shareholder base is undergoing notable shifts, the absence of material changes in the company’s broader financial or operational metrics suggests that Imexpharm Corp’s underlying business trajectory remains unchanged. Investors should monitor these holder adjustments for potential signals of sentiment shifts among major stakeholders, but the current data does not indicate any fundamental alteration to the company’s strategic direction or financial health. The focus remains on interpreting the intent behind these specific share count modifications within the context of the company’s stable corporate structure.

Revenue grew at a 17.8% CAGR over four years, demonstrating strong top-line expansion momentum.

Free cash flow surged 114.2% year-over-year to 350 billion VND, highlighting robust cash generation.

Analysts project 17.6% upside to a mean price target of 55,333 VND, signaling positive market sentiment.

Cash conversion ratio of 0.15 falls in the bottom quartile, suggesting weaker cash generation relative to peers.

Medium liquidity risk flags potential challenges in trading volume or market depth for the stock.

Long-term debt increased to 213 billion VND in FY2026, reversing the previous trend of debt reduction.

Net income growth slowed to 8.8% year-over-year, lagging behind the 10.7% revenue growth rate.

Revenue VND 640.78B, −1,7% YoY; Operating income −11,4% YoY.

• ▍Revenue VND 640.78B, −1,7% YoY
• ▍Operating income −11,4% YoY
• ▍Net income −10,9% YoY
• ▍Free cash flow +39,6% YoY
• ▍Net margin 16.8%

Revenue VND 2.44T, +10,7% YoY; Operating income +10,3% YoY.

• ▍Revenue VND 2.44T, +10,7% YoY
• ▍Operating income +10,3% YoY
• ▍Net income +8,8% YoY
• ▍Free cash flow +114,2% YoY
• ▍Net margin 14.3%

Revenue VND 2.21T, +10,6% YoY; Operating income +7,7% YoY.

• ▍Revenue VND 2.21T, +10,6% YoY
• ▍Operating income +7,7% YoY
• ▍Net income +7,1% YoY
• ▍Free cash flow −35,1% YoY
• ▍Net margin 14.6%

Revenue VND 1.99T, +21,3% YoY; Operating income +28,8% YoY.

• ▍Revenue VND 1.99T, +21,3% YoY
• ▍Operating income +28,8% YoY
• ▍Net income +34,0% YoY
• ▍Free cash flow +198,0% YoY
• ▍Net margin 15.0%

Revenue VND 1.64T, +29,8% YoY; Operating income +23,9% YoY.

• ▍Revenue VND 1.64T, +29,8% YoY
• ▍Operating income +23,9% YoY
• ▍Net income +18,2% YoY
• ▍Free cash flow −12,5% YoY
• ▍Net margin 13.6%

Revenue VND 1.27T; Operating income VND 234.48B.

• ▍Revenue VND 1.27T
• ▍Operating income VND 234.48B
• ▍Net margin 14.9%